Authors: Villalona-Calero, MA Blum, JL Jones, SE Diab, S Elledge, R Khoury, P Von Hoff, D Kraynak, M Moczygemba, J Kromelis, P Griffin, T Rowinsky, EK

Citation: Ma. Villalona-calero et al., A phase I and pharmacologic study of capecitabine and paclitaxel in breastcancer patients, ANN ONCOL, 12(5), 2001, pp. 605-614

Authors: Eckhardt, SG Baker, SD Britten, CD Hidalgo, M Siu, L Hammond, LA Villalona-Calero, MA Felton, S Drengler, R Kuhn, JG Clark, GM Smith, SL MacDonald, JR Smith, C Moczygemba, J Weitman, S Von Hoff, DD Rowinsky, EK

Citation: Sg. Eckhardt et al., Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies, J CL ONCOL, 18(24), 2000, pp. 4086-4097

Authors: Villalona-Calero, MA Weiss, GR Burris, HA Kraynak, M Rodrigues, G Drengler, RL Eckhardt, SG Reigner, B Moczygemba, J Burger, HU Griffin, T Von Hoff, DD Rowinsky, EK

Citation: Ma. Villalona-calero et al., Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies, J CL ONCOL, 17(6), 1999, pp. 1915-1925

Authors: Eckhardt, SG Rizzo, J Sweeney, KR Cropp, G Baker, SD Kraynak, MA Kuhn, JG Villalona-Calero, MA Hammond, L Weiss, G Thurman, A Smith, L Drengler, R Eckardt, JR Moczygemba, J Hannah, AL Von Hoff, DD Rowinsky, EK

Citation: Sg. Eckhardt et al., Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors, J CL ONCOL, 17(4), 1999, pp. 1095-1104